WO2023007441 - TREATMENT OF SLEEP APNEA
National phase entry is expected:
Publication Number
WO/2023/007441
Publication Date
02.02.2023
International Application No.
PCT/IB2022/057025
International Filing Date
28.07.2022
Title **
[English]
TREATMENT OF SLEEP APNEA
[French]
TRAITEMENT DE L'APNÉE DU SOMMEIL
Applicants **
PRIMAVERA BIOSCIENCES, INC.
TAKEDA, Yoshinori
Inventors
TAKEDA, Yoshinori
Priority Data
63/227,528
30.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1035 | |
| EPO | Filing, Examination | 6964 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2280 |
Total:
11,442
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A composition and a method for treating sleep apnea are provided. The method includes the step of administering 5.0 mg to 100.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 12.5 mg to 25.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.[French]
L'invention concerne une composition et un procédé de traitement de l'apnée du sommeil. Le procédé comprend l'étape consistant à administrer 5,0 mg à 100,0 mg d'éphédrine avant d'aller au lit à un patient nécessitant un traitement de l'apnée du sommeil. De préférence, 12,5 mg à 25,0 mg de l'éphédrine sont administrés environ une heure avant d'aller au lit, de l'éphédra contenant 5,0 mg à 100,0 mg de l'éphédrine est administrée, l'éphédrine est administrée 15 à 45 minutes avant d'aller au lit, et/ou l'éphédrine ou l'éphédra contenant l'éphédrine se présente sous la forme d'une libération immédiate, d'une libération prolongée ou d'une libération soutenue.